🏢 官网IRSTTKDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 20:00:00(美东 08:00)时区推断·⟳ 抓取 20:04:13回填·⚡ 决策 10-13 20:06:38·14.4 天前
Shattuck Labs 预告将在 UEG Week 2026 展示两份科研壁报，无临床/监管/财务增量
这是一份典型的临床期生物科技公司会议出席预告：两份壁报分别是 SL-846 临床前表征和 TL1A 机制研究，无人体临床数据、无监管进展、无合作/融资、无财务数字，且壁报全文会后才发布；不构成可交易的新增事实，正期望不存在。
📄 原文STTK↗ 原文
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
NEWS RELEASE Shattuck Labs Announces Two Poster Presentations at UEG Week 2026 2026-10-13 AUSTIN, Texas and DURHAM, N.C…
不做 Shattuck Labs, Inc.（STTK.US）
无新增事实：仅预告 UEG Week 两份临床前/机制性壁报，无临床数据、监管节点、合作或财务指引，壁报正文会后才发布；缺乏方向与 edge，不入场（多空均不做）。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Shattuck Labs 仅预告 UEG Week 2026 上展示两份（临床前/机制性）壁报，无任何临床、监管或商业增量，壁报正文会后才上线；属于常规 IR 日程通告，无交易 edge，回避。
🔎 新鲜度:最早出现 2026-10-13 · 扩散 low · price-in 风险 low ↗
主要风险
- 真正的潜在催化在 10 月 17–20 日壁报正文发布时，若届时披露超预期临床前/早期数据需作为独立新事件重新研判，本次不预判
- 公司为临床期小盘生物科技股，股价可能受板块情绪或 TL1A/DR3 赛道传闻驱动，但那与本稿无关
先例如何影响了这次决策
对本次决策的影响:确认本次不给交易腿；真正的复盘对象应是壁报正文发布事件而非出席预告
方向:无可对照先例；但临床期生物科技公司纯会议壁报预告（不含新临床数据）历史上普遍不构成方向性催化
涨幅量级:无对齐先例可校准幅度，且本事件无增量数据，不应据此设定止盈止损
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 10 ms
{"result": "search_processed_events:agent query=`shattuck labs sttk ueg week 2026 poster presentation sl-846 | shattuck labs tl1a dr3 poster barcelona october 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 2,434 字
NEWS RELEASE
Shattuck Labs Announces Two Poster
Presentations at UEG Week 2026
2026-10-13
AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or
the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of
potential rst-in-class monoclonal and bispeci c DR3 blocking antibodies for the treatment of patients
with in ammatory and immune-mediated diseases, today announced two upcoming poster
presentations at United European Gastroenterology (UEG) Week 2026, taking place October 17–20,
2026, in Barcelona, Spain.
Presentation Details
Format: Moderated poster presentation
Title: Development and Characterization of SL-846: A Half-Life Extended, Dual-Receptor (DR3 x IL23RA)
Targeting Bispeci c Antibody
Presenter: Mahmud Hussain, Ph.D., Director, R&D of Shattuck Labs
Date/Time: October 19, 2026; 1:00–2:00 p.m. CEST
Format: ePoster presentation
Title: Soluble TL1A/Anti-TL1A Immune Complexes Induce De Novo Production of TL1A and Induce Anti-
Drug Antibodies That Cross-Bind Approved IBD Antibodies
Presenter: Suresh de Silva, Ph.D., Chief Scienti c O cer of Shattuck Labs
Date/Time: October 17–20, 2026 (available for viewing throughout the congress)
The posters will be available under Events & Presentations in the Investor Relations section of the
Company’s website at www.shattucklabs.com following the congress.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially
rst-in-class monoclonal and bispeci c DR3 blocking antibodies for the treatment of patients with
in ammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the
development of novel TNF receptor therapeutics come together in its lead program, SL-325, a
potentially rst-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the
clinically validated DR3/TL1A pathway. The Company has o ces in both Austin, Texas and Durham,
1
North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact:
Andrew R. Neill
Chief Financial O cer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Source: Shattuck Labs, Inc.
2
Shattuck Labs Announces Two Poster
Presentations at UEG Week 2026
2026-10-13
AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or
the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of
potential rst-in-class monoclonal and bispeci c DR3 blocking antibodies for the treatment of patients
with in ammatory and immune-mediated diseases, today announced two upcoming poster
presentations at United European Gastroenterology (UEG) Week 2026, taking place October 17–20,
2026, in Barcelona, Spain.
Presentation Details
Format: Moderated poster presentation
Title: Development and Characterization of SL-846: A Half-Life Extended, Dual-Receptor (DR3 x IL23RA)
Targeting Bispeci c Antibody
Presenter: Mahmud Hussain, Ph.D., Director, R&D of Shattuck Labs
Date/Time: October 19, 2026; 1:00–2:00 p.m. CEST
Format: ePoster presentation
Title: Soluble TL1A/Anti-TL1A Immune Complexes Induce De Novo Production of TL1A and Induce Anti-
Drug Antibodies That Cross-Bind Approved IBD Antibodies
Presenter: Suresh de Silva, Ph.D., Chief Scienti c O cer of Shattuck Labs
Date/Time: October 17–20, 2026 (available for viewing throughout the congress)
The posters will be available under Events & Presentations in the Investor Relations section of the
Company’s website at www.shattucklabs.com following the congress.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially
rst-in-class monoclonal and bispeci c DR3 blocking antibodies for the treatment of patients with
in ammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the
development of novel TNF receptor therapeutics come together in its lead program, SL-325, a
potentially rst-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the
clinically validated DR3/TL1A pathway. The Company has o ces in both Austin, Texas and Durham,
1
North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact:
Andrew R. Neill
Chief Financial O cer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Source: Shattuck Labs, Inc.
2
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
6c0b7cb5fb· 2026-10-13 20:06 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前